Literature DB >> 21255997

Searching for synthetic lethality in cancer.

Rachel Brough1, Jessica R Frankum, Sara Costa-Cabral, Christopher J Lord, Alan Ashworth.   

Abstract

The incentive to develop personalised therapy for cancer treatment is driven by the premise that it will increase therapeutic efficacy and reduce toxicity. Understanding the underlying cellular and molecular basis of the disease has been extremely important in the design of these novel therapies; however, identifying new drug targets for personalised therapies remains problematic. This review describes how the biological concept of synthetic lethality has been successfully implemented to identify new therapeutic approaches and targets in models from yeast through to human cells. We also discuss how recent technical advances combined with an increased understanding of the complexity of cellular networks may facilitate therapeutic advances in the future.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21255997     DOI: 10.1016/j.gde.2010.10.009

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  49 in total

1.  Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines.

Authors:  Romel Somwar; Hediye Erdjument-Bromage; Erik Larsson; David Shum; William W Lockwood; Guangli Yang; Chris Sander; Ouathek Ouerfelli; Paul J Tempst; Hakim Djaballah; Harold E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

Review 2.  Collateral sensitivity as a strategy against cancer multidrug resistance.

Authors:  Kristen M Pluchino; Matthew D Hall; Andrew S Goldsborough; Richard Callaghan; Michael M Gottesman
Journal:  Drug Resist Updat       Date:  2012-04-06       Impact factor: 18.500

Review 3.  Repair of strand breaks by homologous recombination.

Authors:  Maria Jasin; Rodney Rothstein
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-11-01       Impact factor: 10.005

Review 4.  Molecular biology of lung cancer: clinical implications.

Authors:  Jill E Larsen; John D Minna
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

Review 5.  Cancer research: past, present and future.

Authors:  Ya Cao; Ronald A DePinho; Matthias Ernst; Karen Vousden
Journal:  Nat Rev Cancer       Date:  2011-09-15       Impact factor: 60.716

Review 6.  Therapeutic targeting of tumor suppressor genes.

Authors:  Luc G T Morris; Timothy A Chan
Journal:  Cancer       Date:  2014-12-29       Impact factor: 6.860

Review 7.  Update: the status of clinical trials with kinase inhibitors in thyroid cancer.

Authors:  Samuel A Wells; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2014-01-13       Impact factor: 5.958

Review 8.  A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.

Authors:  Neil Vasan; Julie L Boyer; Roy S Herbst
Journal:  Clin Cancer Res       Date:  2014-06-03       Impact factor: 12.531

Review 9.  New developments in the treatment of ovarian cancer--future perspectives.

Authors:  J Lopez; S Banerjee; S B Kaye
Journal:  Ann Oncol       Date:  2013-12       Impact factor: 32.976

10.  Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation.

Authors:  David Nittner; Irina Lambertz; Frederic Clermont; Pieter Mestdagh; Corinna Köhler; Søren Jensby Nielsen; Aart Jochemsen; Frank Speleman; Jo Vandesompele; Michael A Dyer; Alexander Schramm; Johannes H Schulte; Jean-Christophe Marine
Journal:  Nat Cell Biol       Date:  2012-08-05       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.